Zentalis Pharmaceuticals
ZNTL
142 hedge funds and large institutions have $1.34B invested in Zentalis Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 14 closing their positions.
3,075% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $36K
157% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 14
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
18% more funds holding
Funds holding: 120 → 142 (+22)
13% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 38
9% more capital invested
Capital invested by funds: $1.24B → $1.34B (+$107M)
4.78% more ownership
Funds ownership: 115.41% → 120.2% (+4.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$20.9M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$13.4M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$11.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.06M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$7.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.68M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
-$3.79M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.34M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$2.95M |
ZNTL Hedge Fund Activity: Q1 2024 in Review
142 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2024, worth a combined $1.34B — up 8.6% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ZNTL positions and 14 closed out — a net gain of 22 holders — while 43 added to existing stakes and 38 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $20.9M. The largest seller was Vanguard Group, cutting an estimated $13.1M.
- 142 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2024, up from 120 in Q4 2023.
- Funds reported $1.34B of Zentalis Pharmaceuticals stock for Q1 2024, up 8.6% quarter-over-quarter.
- 36 funds opened new Zentalis Pharmaceuticals positions in Q1 2024 and 14 closed out, a net change of +22 holders.
- The largest Zentalis Pharmaceuticals buyer in Q1 2024 was MPM BioImpact, an estimated $20.9M added.
- The largest Zentalis Pharmaceuticals seller in Q1 2024 was Vanguard Group, an estimated $13.1M sold.
Based on aggregated 13F filings for Q1 2024.